Skip to content
OpenCapital
Get started

AtriCure ATRC Free cash flow

Free cash flow at other companies

Abbott logo
AbbottABT
$916M-1.8%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.47B-56.6%
Boston Scientific logo
Boston ScientificBSX
$171M-51.7%
Medtronic logo
MedtronicMDT
$2.09B+0.8%
Pulse Biosciences, Inc. logo
Pulse Biosciences, Inc.PLSE
-$14.63M-7.8%
ITG
Integer HoldingsITGR
$737K-87.8%

Other financials

Income statement

See full
Revenue$141.2M+14.3%
Gross profit$109.3M+18.0%
Operating income$526.0K+109%
Net income$108.0K+102%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$146.2M+46.3%
Total debt$76.2M-3.1%
Total equity$491.7M+8.2%
Total assets$644.0M+8.8%

Cash flow

See full
Operating cash flow-$4.0M+63.8%
CapEx$3.9M+76.6%

Valuation

See full
Market cap$1.43B-9.9%
Enterprise value$1.36B-13.1%
P/S2.6×-0.7×

Profitability

See full
Gross margin75.6%+0.8pp
Operating margin-5.1%-1.3pp
Net margin-5.6%-1.5pp
FCF margin9.7%—

Returns & leverage

See full
Return on equity-6.1%-1.3pp
Debt / equity0.2×0.0×
Current ratio4.3×+0.2×

Where this comes from

Calculated from AtriCure’s reported figures.

−$4.0Mnet cash from operating−$3.9Mcapital expenditures=-$7.85M

The official record: AtriCure’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about AtriCure's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AtriCure's free cash flow?
AtriCure (ATRC) reported free cash flow of -$7.85M in Q1 2026.
How has AtriCure's free cash flow changed year-over-year?
AtriCure's free cash flow increased by 40.6% year-over-year, from -$13.21M to -$7.85M.
What is the long-term trend for AtriCure's free cash flow?
Over 2 years (2021 to 2025), AtriCure's free cash flow has grown at a 43.2% compound annual growth rate (CAGR), from -$23.53M to $48.28M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.